

My information

Name:

Date of birth

DD / MM / YYYY

Phone number:

Emergency contact (name):

Emergency contact (phone number):

NHS number:

My treatment details

Please complete this section or ask your doctor to do it.

Start date: DD / MM / YYYY

End date: DD / MM / YYYY

It is important to record the end date of your treatment because isatuximab may interfere with the indirect antiglobulin test (indirect Coombs test) for at least 6 months after the last infusion.

My blood results

Before starting isatuximab, the results of my blood test collected on DD / MM / YYYY were:

Blood type:

A

B

AB

O

Rh+

Rh-

The result of my indirect antiglobulin test (indirect Coombs test) was:

Negative

Positive for the following antibodies:

Other

Contact details of institution where blood test was performed:

Phone number

My haematologist's information

In case of emergency, or if you find this card, please contact my haematologist using the details below.

Haematologist's name:

[REDACTED]

Haematologist's phone number:

[REDACTED]

Name of hospital:

[REDACTED]

VV-PV-0627239 (v1.0) | Date of preparation: January 2026

Date of MHRA Approval: January 2026

sanofi

This material fulfills the conditions of the marketing authorisation and has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA).

SARCLISA® (isatuximab)

Patient card

For patients receiving isatuximab

- Provide this card to healthcare providers before blood transfusion.
- Keep this card with you at all times and for at least 6 months after the last dose of isatuximab.
- If you notice any side effects, talk to your doctor or pharmacist.
- Please report side effects to the MHRA through the Yellow Card Scheme, via the Yellow Card website www.mhra.gov.uk/yellowcard or the free Yellow Card app available in [Apple App Store](#) or [Google Play Store](#). Alternatively, you can call 0800 731 6789 for free, Monday to Friday between 9am and 5pm. By reporting side effects, you can help provide more information on the safety of this medicine. Side effects can also be reported to Sanofi: Tel: 0800 090 2314; email: uk-drugsafety@sanofi.com
- For further information about isatuximab, you can consult the Patient Information Leaflet (PIL).

Warning message for healthcare professionals treating the patient at any time, including in emergency situations:

- Please note this patient is receiving treatment with isatuximab for the treatment of multiple myeloma.
- This patient card contains important safety information that you need to be aware of before, during, and after treatment with isatuximab.
- Isatuximab can bind to CD38 on red blood cells (RBCs) and is associated with a risk of interference with blood typing (positive indirect Coombs test), which may persist for at least 6 months after the last isatuximab infusion.
- To avoid potential problems with RBC transfusion, you should perform blood type and screen tests prior to the first infusion of isatuximab. Phenotyping may be considered as per local practice.
- If treatment with isatuximab has already started and in the event of a planned transfusion, you should notify the blood bank that the patient is receiving isatuximab and alert them to the risk of interference with the indirect antiglobulin test (indirect Coombs test).
- For additional information about isatuximab, please refer to the Summary of Product Characteristics (SmPC).